BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bruni D, Angell HK, Galon J. The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy. Nat Rev Cancer 2020;20:662-80. [PMID: 32753728 DOI: 10.1038/s41568-020-0285-7] [Cited by in Crossref: 122] [Cited by in F6Publishing: 132] [Article Influence: 61.0] [Reference Citation Analysis]
Number Citing Articles
1 Almangush A, Leivo I, Mäkitie AA. Biomarkers for Immunotherapy of Oral Squamous Cell Carcinoma: Current Status and Challenges. Front Oncol 2021;11:616629. [PMID: 33763354 DOI: 10.3389/fonc.2021.616629] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 Perrier A, Hainaut P, Lamy PJ, Guenoun A, Nguyen DP, Guerber F, Troalen F, Denis JA, Boissan M. [Clinical use and evolution of circulating biomarkers in the era of personalized oncology: From protein markers to bioclinical scores]. Bull Cancer 2022:S0007-4551(21)00574-9. [PMID: 35012767 DOI: 10.1016/j.bulcan.2021.11.010] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Elomaa H, Ahtiainen M, Väyrynen SA, Ogino S, Nowak JA, Friman M, Helminen O, Wirta EV, Seppälä TT, Böhm J, Mäkinen MJ, Mecklin JP, Kuopio T, Väyrynen JP. Prognostic significance of spatial and density analysis of T lymphocytes in colorectal cancer. Br J Cancer 2022. [PMID: 35449453 DOI: 10.1038/s41416-022-01822-6] [Reference Citation Analysis]
4 Li J, Han T, Wang X, Wang Y, Chen X, Chen W, Yang Q. Construction of a Novel Immune-Related mRNA Signature to Predict the Prognosis and Immune Characteristics of Human Colorectal Cancer. Front Genet 2022;13:851373. [DOI: 10.3389/fgene.2022.851373] [Reference Citation Analysis]
5 Zhang Y, Chen X, Fu Q, Wang F, Zhou X, Xiang J, He N, Hu Z, Jin X. Comprehensive analysis of pyroptosis regulators and tumor immune microenvironment in clear cell renal cell carcinoma. Cancer Cell Int 2021;21:667. [PMID: 34906145 DOI: 10.1186/s12935-021-02384-y] [Reference Citation Analysis]
6 Wang T, Denman D, Bacot SM, Feldman GM. Challenges and the Evolving Landscape of Assessing Blood-Based PD-L1 Expression as a Biomarker for Anti-PD-(L)1 Immunotherapy. Biomedicines 2022;10:1181. [DOI: 10.3390/biomedicines10051181] [Reference Citation Analysis]
7 Feng B, Hess J. Immune-Related Mutational Landscape and Gene Signatures: Prognostic Value and Therapeutic Impact for Head and Neck Cancer. Cancers (Basel) 2021;13:1162. [PMID: 33800421 DOI: 10.3390/cancers13051162] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Schmitt M, Greten FR. The inflammatory pathogenesis of colorectal cancer. Nat Rev Immunol 2021. [PMID: 33911231 DOI: 10.1038/s41577-021-00534-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
9 Ouyang W, Jiang Y, Bu S, Tang T, Huang L, Chen M, Tan Y, Ou Q, Mao L, Mai Y, Yao H, Yu Y, Lin X. A Prognostic Risk Score Based on Hypoxia-, Immunity-, and Epithelialto-Mesenchymal Transition-Related Genes for the Prognosis and Immunotherapy Response of Lung Adenocarcinoma. Front Cell Dev Biol 2022;9:758777. [DOI: 10.3389/fcell.2021.758777] [Reference Citation Analysis]
10 Eberst G, Vernerey D, Laheurte C, Meurisse A, Kaulek V, Cuche L, Jacoulet P, Almotlak H, Lahourcade J, Gainet-Brun M, Fabre E, Le Pimpec-Barthes F, Adotevi O, Westeel V. Prognostic value of CD4+ T lymphopenia in non-small cell lung Cancer. BMC Cancer 2022;22:529. [PMID: 35546670 DOI: 10.1186/s12885-022-09628-8] [Reference Citation Analysis]
11 Xue L, Wu P, Zhao X, Jin X, Wang J, Shi Y, Yang X, She Y, Li Y, Li C. Using Immune-Related lncRNA Signature for Prognosis and Response to Immunotherapy in Cutaneous Melanoma. Int J Gen Med 2021;14:6463-75. [PMID: 34675614 DOI: 10.2147/IJGM.S335266] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Eptaminitaki GC, Wolff N, Stellas D, Sifakis K, Baritaki S. Long Non-Coding RNAs (lncRNAs) in Response and Resistance to Cancer Immunosurveillance and Immunotherapy. Cells 2021;10:3313. [PMID: 34943820 DOI: 10.3390/cells10123313] [Reference Citation Analysis]
13 Armitage JD, Newnes HV, McDonnell A, Bosco A, Waithman J. Fine-Tuning the Tumour Microenvironment: Current Perspectives on the Mechanisms of Tumour Immunosuppression. Cells 2021;10:E56. [PMID: 33401460 DOI: 10.3390/cells10010056] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
14 Rossi A, Pacella I, Piconese S. RNA Flow Cytometry for the Study of T Cell Metabolism. Int J Mol Sci 2021;22:3906. [PMID: 33918901 DOI: 10.3390/ijms22083906] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Maby P, Bindea G, Mlecnik B, Galon J. License to kill: microsatellite instability and immune contexture. Oncoimmunology 2021;10:1905935. [PMID: 33868790 DOI: 10.1080/2162402X.2021.1905935] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
16 Li Y, Lu S, Wang S, Peng X, Lang J. Identification of immune subtypes of cervical squamous cell carcinoma predicting prognosis and immunotherapy responses. J Transl Med 2021;19:222. [PMID: 34030694 DOI: 10.1186/s12967-021-02894-3] [Reference Citation Analysis]
17 Shi H, Li K, Ni Y, Liang X, Zhao X. Myeloid-Derived Suppressor Cells: Implications in the Resistance of Malignant Tumors to T Cell-Based Immunotherapy. Front Cell Dev Biol 2021;9:707198. [PMID: 34336860 DOI: 10.3389/fcell.2021.707198] [Reference Citation Analysis]
18 Fucikova J, Palova-Jelinkova L, Klapp V, Holicek P, Lanickova T, Kasikova L, Drozenova J, Cibula D, Álvarez-Abril B, García-Martínez E, Spisek R, Galluzzi L. Immunological control of ovarian carcinoma by chemotherapy and targeted anticancer agents. Trends Cancer 2022:S2405-8033(22)00017-6. [PMID: 35181272 DOI: 10.1016/j.trecan.2022.01.010] [Reference Citation Analysis]
19 Zheng X, Li L, Yu C, Yang J, Zhao Y, Su C, Yu J, Xu M. Establishment of a tumor immune microenvironment-based molecular classification system of breast cancer for immunotherapy. Aging (Albany NY) 2021;13:24313-38. [PMID: 34762599 DOI: 10.18632/aging.203682] [Reference Citation Analysis]
20 Lin X, Qiu G, Li F, Deng H, Qin Y, Xie X, Jiang J, Song Y, Liu M, Zhou C. Case Report: A Rare Case of Metachronous Multiple Primary Lung Cancers in a Patient With Successful Management by Switching From Anti-PD-1 Therapy to Anti-PD-L1 Therapy. Front Immunol 2021;12:683202. [PMID: 34149722 DOI: 10.3389/fimmu.2021.683202] [Reference Citation Analysis]
21 Marliot F, Pagès F, Galon J. Usefulness and robustness of Immunoscore for personalized management of cancer patients. Oncoimmunology 2020;9:1832324. [PMID: 33194318 DOI: 10.1080/2162402X.2020.1832324] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
22 Geidel G, Heidrich I, Kött J, Schneider SW, Pantel K, Gebhardt C. Emerging precision diagnostics in advanced cutaneous squamous cell carcinoma. NPJ Precis Oncol 2022;6:17. [PMID: 35322182 DOI: 10.1038/s41698-022-00261-z] [Reference Citation Analysis]
23 Liu YT, Sun ZJ. Turning cold tumors into hot tumors by improving T-cell infiltration. Theranostics 2021;11:5365-86. [PMID: 33859752 DOI: 10.7150/thno.58390] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
24 An Y, Zhou J, Lin G, Wu H, Cong L, Li Y, Qiu X, Shi W. Clinicopathological and Molecular Characteristics of Colorectal Signet Ring Cell Carcinoma: A Review. Pathol Oncol Res 2021;27:1609859. [PMID: 34381313 DOI: 10.3389/pore.2021.1609859] [Reference Citation Analysis]
25 Sayaman RW, Saad M, Thorsson V, Hu D, Hendrickx W, Roelands J, Porta-Pardo E, Mokrab Y, Farshidfar F, Kirchhoff T, Sweis RF, Bathe OF, Heimann C, Campbell MJ, Stretch C, Huntsman S, Graff RE, Syed N, Radvanyi L, Shelley S, Wolf D, Marincola FM, Ceccarelli M, Galon J, Ziv E, Bedognetti D. Germline genetic contribution to the immune landscape of cancer. Immunity. 2021;54:367-386.e8. [PMID: 33567262 DOI: 10.1016/j.immuni.2021.01.011] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
26 Lin J, Cao Z, Yu D, Cai W. Identification of Transcription Factor-Related Gene Signature and Risk Score Model for Colon Adenocarcinoma. Front Genet 2021;12:709133. [PMID: 34603375 DOI: 10.3389/fgene.2021.709133] [Reference Citation Analysis]
27 Pan X, Zhang C, Wang J, Wang P, Gao Y, Shang S, Guo S, Li X, Zhi H, Ning S. Epigenome signature as an immunophenotype indicator prompts durable clinical immunotherapy benefits in lung adenocarcinoma. Brief Bioinform 2021:bbab481. [PMID: 34864866 DOI: 10.1093/bib/bbab481] [Reference Citation Analysis]
28 Kasi A, Dotan E, Poage GM, Catteau A, Vernerey D, George M, Barzi A. Impact of Immunoscore on the Management of Stage II Colon Cancer Patients: A Physician Survey. Cancers (Basel) 2021;13:5467. [PMID: 34771628 DOI: 10.3390/cancers13215467] [Reference Citation Analysis]
29 Sonanini D, Griessinger CM, Schörg BF, Knopf P, Dittmann K, Röcken M, Pichler BJ, Kneilling M. Low-dose total body irradiation facilitates antitumoral Th1 immune responses. Theranostics 2021;11:7700-14. [PMID: 34335959 DOI: 10.7150/thno.61459] [Reference Citation Analysis]
30 Veigas F, Mahmoud YD, Merlo J, Rinflerch A, Rabinovich GA, Girotti MR. Immune Checkpoints Pathways in Head and Neck Squamous Cell Carcinoma. Cancers (Basel) 2021;13:1018. [PMID: 33804419 DOI: 10.3390/cancers13051018] [Reference Citation Analysis]
31 Laumont CM, Nelson BH. IgA transcytosis: A new weapon in the immune response to cancer? Cancer Cell 2021;39:607-9. [PMID: 33974859 DOI: 10.1016/j.ccell.2021.04.007] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
32 Xie Y, Olkhov-Mitsel E, Alminawi S, Slodkowska E, Downes MR. Development of a multiplex immuno-oncology biomarker and digital pathology workflow for assessment of urothelial carcinoma. Pathol Res Pract 2021;226:153607. [PMID: 34509050 DOI: 10.1016/j.prp.2021.153607] [Reference Citation Analysis]
33 Shen YJ, Qian LQ, Ding ZP, Luo QQ, Zhao H, Xia WY, Fu YY, Feng W, Zhang Q, Yu W, Cai XW, Fu XL. Prognostic Value of Inflammatory Biomarkers in Patients With Stage I Lung Adenocarcinoma Treated With Surgical Dissection. Front Oncol 2021;11:711206. [PMID: 34540678 DOI: 10.3389/fonc.2021.711206] [Reference Citation Analysis]
34 Munari E, Marconi M, Querzoli G, Lunardi G, Bertoglio P, Ciompi F, Tosadori A, Eccher A, Tumino N, Quatrini L, Vacca P, Rossi G, Cavazza A, Martignoni G, Brunelli M, Netto GJ, Moretta L, Zamboni G, Bogina G. Impact of PD-L1 and PD-1 Expression on the Prognostic Significance of CD8+ Tumor-Infiltrating Lymphocytes in Non-Small Cell Lung Cancer. Front Immunol 2021;12:680973. [PMID: 34122444 DOI: 10.3389/fimmu.2021.680973] [Reference Citation Analysis]
35 Xian D, Niu L, Zeng J, Wang L. LncRNA KCNQ1OT1 Secreted by Tumor Cell-Derived Exosomes Mediates Immune Escape in Colorectal Cancer by Regulating PD-L1 Ubiquitination via MiR-30a-5p/USP22. Front Cell Dev Biol 2021;9:653808. [PMID: 34350172 DOI: 10.3389/fcell.2021.653808] [Reference Citation Analysis]
36 Chen Y, Meng Z, Zhang L, Liu F. CD2 Is a Novel Immune-Related Prognostic Biomarker of Invasive Breast Carcinoma That Modulates the Tumor Microenvironment. Front Immunol 2021;12:664845. [PMID: 33968066 DOI: 10.3389/fimmu.2021.664845] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
37 Aye L, Song X, Yang J, Hu L, Sun X, Zhou J, Liu Q, Yu H, Wang D. Identification of a Costimulatory Molecule Gene Signature to Predict Survival and Immunotherapy Response in Head and Neck Squamous Cell Carcinoma. Front Cell Dev Biol 2021;9:695533. [PMID: 34434928 DOI: 10.3389/fcell.2021.695533] [Reference Citation Analysis]
38 Atsou K, Anjuère F, Braud VM, Goudon T. A size and space structured model of tumor growth describes a key role for protumor immune cells in breaking equilibrium states in tumorigenesis. PLoS One 2021;16:e0259291. [PMID: 34808661 DOI: 10.1371/journal.pone.0259291] [Reference Citation Analysis]
39 Ascierto PA, Bifulco C, Ciardiello F, Demaria S, Emens LA, Ferris R, Formenti SC, Galon J, Khleif SN, Kirchhoff T, McQuade J, Odunsi K, Patnaik A, Paulos CM, Taube JM, Timmerman J, Fox BA, Hwu P, Puzanov I. Perspectives in immunotherapy: meeting report from the immunotherapy bridge (December 2nd-3rd, 2020, Italy). J Transl Med 2021;19:238. [PMID: 34078406 DOI: 10.1186/s12967-021-02895-2] [Reference Citation Analysis]
40 Wang S, Chen S, Ying Y, Ma X, Shen H, Li J, Wang X, Lin Y, Liu B, Zheng X, Xie L. Comprehensive Analysis of Ferroptosis Regulators With Regard to PD-L1 and Immune Infiltration in Clear Cell Renal Cell Carcinoma. Front Cell Dev Biol 2021;9:676142. [PMID: 34291048 DOI: 10.3389/fcell.2021.676142] [Reference Citation Analysis]
41 Lu N, Liu J, Ji C, Wang Y, Wu Z, Yuan S, Xing Y, Diao F. MiRNA based tumor mutation burden diagnostic and prognostic prediction models for endometrial cancer. Bioengineered 2021;12:3603-20. [PMID: 34252354 DOI: 10.1080/21655979.2021.1947940] [Reference Citation Analysis]
42 Cendrowicz E, Sas Z, Bremer E, Rygiel TP. The Role of Macrophages in Cancer Development and Therapy. Cancers (Basel) 2021;13:1946. [PMID: 33919517 DOI: 10.3390/cancers13081946] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
43 Economopoulou P, Kotsantis I, Psyrri A. Tumor Microenvironment and Immunotherapy Response in Head and Neck Cancer. Cancers (Basel) 2020;12:E3377. [PMID: 33203092 DOI: 10.3390/cancers12113377] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
44 Cerboni S, Gehrmann U, Preite S, Mitra S. Cytokine-regulated Th17 plasticity in human health and diseases. Immunology 2021;163:3-18. [PMID: 33064842 DOI: 10.1111/imm.13280] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
45 Lam KC, Araya RE, Huang A, Chen Q, Di Modica M, Rodrigues RR, Lopès A, Johnson SB, Schwarz B, Bohrnsen E, Cogdill AP, Bosio CM, Wargo JA, Lee MP, Goldszmid RS. Microbiota triggers STING-type I IFN-dependent monocyte reprogramming of the tumor microenvironment. Cell 2021;184:5338-5356.e21. [PMID: 34624222 DOI: 10.1016/j.cell.2021.09.019] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
46 Agarwal P, Le DT, Boland PM. Immunotherapy in colorectal cancer. Adv Cancer Res 2021;151:137-96. [PMID: 34148613 DOI: 10.1016/bs.acr.2021.03.002] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
47 Zhang L, Chen Y, Wang H, Xu Z, Wang Y, Li S, Liu J, Chen Y, Luo H, Wu L, Yang Y, Zhang H, Peng H. Massive PD-L1 and CD8 double positive TILs characterize an immunosuppressive microenvironment with high mutational burden in lung cancer. J Immunother Cancer 2021;9:e002356. [PMID: 34140315 DOI: 10.1136/jitc-2021-002356] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
48 Kraehenbuehl L, Weng CH, Eghbali S, Wolchok JD, Merghoub T. Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways. Nat Rev Clin Oncol 2021. [PMID: 34580473 DOI: 10.1038/s41571-021-00552-7] [Reference Citation Analysis]
49 Li J, Xie Y, Huang Z, Shen D, Zhuang Z, Zhu M, Huang Y, He R, Wang X, Huang M, Luo Y, Yu H. Current treatment and surveillance modalities are not sufficient for advanced stage III colon cancer: Result from a multicenter cohort analysis. Cancer Med 2021. [PMID: 34786881 DOI: 10.1002/cam4.4417] [Reference Citation Analysis]
50 Wang N, Li X, Wang R, Ding Z. Spatial transcriptomics and proteomics technologies for deconvoluting the tumor microenvironment. Biotechnol J 2021;:e2100041. [PMID: 34125481 DOI: 10.1002/biot.202100041] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
51 Zhang Y, Zhang K, Gong H, Li Q, Man L, Jin Q, Zhang L, Li S. Links Between N6-Methyladenosine and Tumor Microenvironments in Colorectal Cancer. Front Cell Dev Biol 2022;10:807129. [DOI: 10.3389/fcell.2022.807129] [Reference Citation Analysis]
52 Bamodu OA, Wang YH, Yeh CT, Ho CH, Chiang YT, Kao WT, Liu CH, Wu CC. Concomitant High Apoptosis Inhibitor of Macrophage (AIM) and Low Prostate-Specific Antigen (PSA) Indicates Activated T Cell-Mediated Anticancer Immunity, Enhance Sensitivity to Pembrolizumab, and Elicit Good Prognosis in Prostate Cancer. Biomedicines 2021;9:1225. [PMID: 34572412 DOI: 10.3390/biomedicines9091225] [Reference Citation Analysis]
53 Shen J, Shen H, Ke L, Chen J, Dang X, Liu B, Hua Y. Knowledge Mapping of Immunotherapy for Hepatocellular Carcinoma: A Bibliometric Study. Front Immunol 2022;13:815575. [DOI: 10.3389/fimmu.2022.815575] [Reference Citation Analysis]
54 Liu L, Zhang R, Deng J, Dai X, Zhu X, Fu Q, Zhang H, Tong Z, Zhao P, Fang W, Zheng Y, Bao X. Construction of TME and Identification of crosstalk between malignant cells and macrophages by SPP1 in hepatocellular carcinoma. Cancer Immunol Immunother 2021. [PMID: 34028567 DOI: 10.1007/s00262-021-02967-8] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
55 Fan B, Ji K, Bu Z, Zhang J, Yang H, Li J, Wu X. ARHGAP11A Is a Prognostic Biomarker and Correlated With Immune Infiltrates in Gastric Cancer. Front Mol Biosci 2021;8:720645. [PMID: 34733886 DOI: 10.3389/fmolb.2021.720645] [Reference Citation Analysis]
56 Garland KM, Rosch JC, Carson CS, Wang-Bishop L, Hanna A, Sevimli S, Van Kaer C, Balko JM, Ascano M, Wilson JT. Pharmacological Activation of cGAS for Cancer Immunotherapy. Front Immunol 2021;12:753472. [PMID: 34899704 DOI: 10.3389/fimmu.2021.753472] [Reference Citation Analysis]
57 Zhao H, Han B, Li X, Sun C, Zhai Y, Li M, Jiang M, Zhang W, Liang Y, Kai G. Salvia miltiorrhiza in Breast Cancer Treatment: A Review of Its Phytochemistry, Derivatives, Nanoparticles, and Potential Mechanisms. Front Pharmacol 2022;13:872085. [DOI: 10.3389/fphar.2022.872085] [Reference Citation Analysis]
58 Rischin D, Mehanna H, Young RJ, Bressel M, Dunn J, Corry J, Soni P, Fulton-Lieuw T, Iqbal G, Kenny L, Porceddu S, Wratten C, Robinson M, Solomon BJ; Trans-Tasman Radiation Oncology Group and the De-ESCALaTE HPV Trial Group. Prognostic stratification of HPV associated oropharyngeal cancer based on CD103+ immune cell abundance in patients treated on TROG 12.01 and De-ESCALaTE randomised trials. Ann Oncol 2022:S0923-7534(22)00764-5. [PMID: 35525376 DOI: 10.1016/j.annonc.2022.04.074] [Reference Citation Analysis]
59 Pittet MJ, Michielin O, Migliorini D. Clinical relevance of tumour-associated macrophages. Nat Rev Clin Oncol 2022. [PMID: 35354979 DOI: 10.1038/s41571-022-00620-6] [Reference Citation Analysis]
60 Traenkle B, Kaiser PD, Pezzana S, Richardson J, Gramlich M, Wagner TR, Seyfried D, Weldle M, Holz S, Parfyonova Y, Nueske S, Scholz AM, Zeck A, Jakobi M, Schneiderhan-Marra N, Schaller M, Maurer A, Gouttefangeas C, Kneilling M, Pichler BJ, Sonanini D, Rothbauer U. Single-Domain Antibodies for Targeting, Detection, and In Vivo Imaging of Human CD4+ Cells. Front Immunol 2021;12:799910. [PMID: 34956237 DOI: 10.3389/fimmu.2021.799910] [Reference Citation Analysis]
61 Ji Q, Cai Y, Shrestha SM, Shen D, Zhao W, Shi R. Construction and Validation of an Immune-Related Gene Prognostic Index for Esophageal Squamous Cell Carcinoma. Biomed Res Int 2021;2021:7430315. [PMID: 34722771 DOI: 10.1155/2021/7430315] [Reference Citation Analysis]
62 Bergsland CH, Jeanmougin M, Moosavi SH, Svindland A, Bruun J, Nesbakken A, Sveen A, Lothe RA. Spatial analysis and CD25-expression identify regulatory T cells as predictors of a poor prognosis in colorectal cancer. Mod Pathol 2022. [PMID: 35484226 DOI: 10.1038/s41379-022-01086-8] [Reference Citation Analysis]
63 Khadirnaikar S, Chatterjee A, Shukla SK. Genetic and Epigenetic landscape of leukocyte infiltration identifies an immune prognosticator in lung adenocarcinoma. Cancer Biomark 2021. [PMID: 34275893 DOI: 10.3233/CBM-203071] [Reference Citation Analysis]
64 Llovet JM, Castet F, Heikenwalder M, Maini MK, Mazzaferro V, Pinato DJ, Pikarsky E, Zhu AX, Finn RS. Immunotherapies for hepatocellular carcinoma. Nat Rev Clin Oncol 2021. [PMID: 34764464 DOI: 10.1038/s41571-021-00573-2] [Reference Citation Analysis]
65 Zhang Y, Wang H, Xu X, Liu H, Hao T, Yin S, Zhang C, He Y. Poor Prognosis and Therapeutic Responses in LILRB1-Expressing M2 Macrophages-Enriched Gastric Cancer Patients. Front Oncol 2021;11:668707. [PMID: 34485116 DOI: 10.3389/fonc.2021.668707] [Reference Citation Analysis]
66 Accogli T, Bruchard M, Végran F. Modulation of CD4 T Cell Response According to Tumor Cytokine Microenvironment. Cancers (Basel) 2021;13:373. [PMID: 33498483 DOI: 10.3390/cancers13030373] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
67 Yu H, Zhang D, Lian M. Identification of an epigenetic prognostic signature for patients with lower-grade gliomas. CNS Neurosci Ther 2021;27:470-83. [PMID: 33459509 DOI: 10.1111/cns.13587] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
68 Yang Y, Feng M, Bai L, Liao W, Zhou K, Zhang M, Wu Q, Wen F, Lei W, Zhang P, Zhang N, Huang J, Li Q. Comprehensive analysis of EMT-related genes and lncRNAs in the prognosis, immunity, and drug treatment of colorectal cancer. J Transl Med 2021;19:391. [PMID: 34526059 DOI: 10.1186/s12967-021-03065-0] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
69 Chengcheng L, Wenwen Q, Ningyue G, Fangyuan Z, Runtong X, Zhenxiao T, Fenglei X, Yiming Q, Miaoqing Z, Xiaoming L, Ming X. Identification of the Immune-Related Genes in Tumor Microenvironment That Associated With the Recurrence of Head and Neck Squamous Cell Carcinoma. Front Cell Dev Biol 2021;9:723721. [PMID: 34490269 DOI: 10.3389/fcell.2021.723721] [Reference Citation Analysis]
70 Qi J, Liu X, Yan P, He S, Lin Y, Huang Z, Zhang S, Xie S, Li Y, Lu X, Wu Y, Zhou Y, Yuan J, Cai T, Zheng X, Ding Y, Yang W. Analysis of Immune Landscape Reveals Prognostic Significance of Cytotoxic CD4+ T Cells in the Central Region of pMMR CRC. Front Oncol 2021;11:724232. [PMID: 34631551 DOI: 10.3389/fonc.2021.724232] [Reference Citation Analysis]
71 Caronni N, Montaldo E, Mezzanzanica L, Cilenti F, Genua M, Ostuni R. Determinants, mechanisms, and functional outcomes of myeloid cell diversity in cancer. Immunol Rev 2021;300:220-36. [PMID: 33565148 DOI: 10.1111/imr.12944] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
72 Haddad R, Zlotnik O, Goshen-lago T, Levi M, Brook E, Brenner B, Kundel Y, Ben-aharon I, Kashtan H. Tumor Lymphocyte Infiltration Is Correlated with a Favorable Tumor Regression Grade after Neoadjuvant Treatment for Esophageal Adenocarcinoma. JPM 2022;12:627. [DOI: 10.3390/jpm12040627] [Reference Citation Analysis]
73 Nassif EF, Mlecnik B, Thibault C, Auvray M, Bruni D, Colau A, Compérat E, Bindea G, Catteau A, Fugon A, Boquet I, Martel M, Camparo P, Colin P, Zakopoulou R, Bamias A, Bennamoun M, Barthere X, D'acremont B, Lefevre M, Audenet F, Mejean A, Verkarre V, Oudard S, Galon J. The Immunoscore in Localized Urothelial Carcinoma Treated with Neoadjuvant Chemotherapy: Clinical Significance for Pathologic Responses and Overall Survival. Cancers (Basel) 2021;13:494. [PMID: 33525361 DOI: 10.3390/cancers13030494] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
74 Ascierto PA, Marincola FM, Fox BA, Galon J. No time to die: the consensus immunoscore for predicting survival and response to chemotherapy of locally advanced colon cancer patients in a multicenter international study. Oncoimmunology 2020;9:1826132. [PMID: 33194317 DOI: 10.1080/2162402X.2020.1826132] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
75 Bindea G, Mlecnik B, Galon J. Expand to shield: IL-15 and in situ lymphocytic proliferation. Oncoimmunology 2021;10:1886726. [PMID: 33628626 DOI: 10.1080/2162402X.2021.1886726] [Reference Citation Analysis]
76 Stern PL, Dalianis T. Oropharyngeal Squamous Cell Carcinoma Treatment in the Era of Immune Checkpoint Inhibitors. Viruses 2021;13:1234. [PMID: 34202255 DOI: 10.3390/v13071234] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
77 Hu C, Zhao L, Liu W, Fan S, Liu J, Liu Y, Liu X, Shu L, Liu X, Liu P, Deng C, Qiu Z, Chen C, Jiang Y, Liang Q, Yang L, Shao Y, He Q, Yu D, Zeng Y, Li Y, Pan Y, Zhang S, Shi S, Peng Y, Wu F. Genomic profiles and their associations with TMB, PD-L1 expression, and immune cell infiltration landscapes in synchronous multiple primary lung cancers. J Immunother Cancer 2021;9:e003773. [PMID: 34887263 DOI: 10.1136/jitc-2021-003773] [Reference Citation Analysis]
78 Linares JF, Zhang X, Martinez-Ordoñez A, Duran A, Kinoshita H, Kasashima H, Nakanishi N, Nakanishi Y, Carelli R, Cappelli L, Arias E, Yashiro M, Ohira M, Patel S, Inghirami G, Loda M, Cuervo AM, Diaz-Meco MT, Moscat J. PKCλ/ι inhibition activates an ULK2-mediated interferon response to repress tumorigenesis. Mol Cell 2021;81:4509-4526.e10. [PMID: 34560002 DOI: 10.1016/j.molcel.2021.08.039] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
79 Hochheiser K, Gyorki DE, Gebhardt T. Tumor reactivity of CD8+ T cells favors acquisition of dysfunctional states in human melanoma. Immunol Cell Biol 2021;99:914-6. [PMID: 34545624 DOI: 10.1111/imcb.12498] [Reference Citation Analysis]
80 Kirilovsky A, Sissy CE, Zeitoun G, Marliot F, Haicheur N, Lagorce-Pagès C, Taieb J, Karoui M, Custers P, Dizdarevic E, Iseas S, Hansen TF, Jensen LH, Beets G, Gérard JP, Castillo-Martin M, Figueiredo N, Habr-Gama A, Perez R, Galon J, Pagès F. The "Immunoscore" in rectal cancer: could we search quality beyond quantity of life? Oncotarget 2022;13:18-31. [PMID: 35018217 DOI: 10.18632/oncotarget.28100] [Reference Citation Analysis]
81 Galmiche A, Rak J, Roumenina LT, Saidak Z. Coagulome and the tumor microenvironment: an actionable interplay. Trends Cancer 2022:S2405-8033(21)00261-2. [PMID: 35027336 DOI: 10.1016/j.trecan.2021.12.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
82 Ronen D, Bsoul A, Lotem M, Abedat S, Yarkoni M, Amir O, Asleh R. Exploring the Mechanisms Underlying the Cardiotoxic Effects of Immune Checkpoint Inhibitor Therapies. Vaccines 2022;10:540. [DOI: 10.3390/vaccines10040540] [Reference Citation Analysis]
83 Bindea G, Mlecnik B, Galon J. Immune sunrise: from the immunome to the cancer immune landscape. OncoImmunology 2022;11:2019896. [DOI: 10.1080/2162402x.2021.2019896] [Reference Citation Analysis]
84 Wojas-Krawczyk K, Paśnik I, Kucharczyk T, Wieleba I, Krzyżanowska N, Gil M, Krawczyk P, Milanowski J. Immunoprofiling: An Encouraging Method for Predictive Factors Examination in Lung Cancer Patients Treated with Immunotherapy. Int J Mol Sci 2021;22:9133. [PMID: 34502043 DOI: 10.3390/ijms22179133] [Reference Citation Analysis]
85 Bozic T, Sersa G, Kranjc Brezar S, Cemazar M, Markelc B. Gene electrotransfer of proinflammatory chemokines CCL5 and CCL17 as a novel approach of modifying cytokine expression profile in the tumor microenvironment. Bioelectrochemistry 2021;140:107795. [PMID: 33789177 DOI: 10.1016/j.bioelechem.2021.107795] [Reference Citation Analysis]
86 Ye R, Zeng H, Liu Z, Jin K, Liu C, Yan S, Yu Y, You R, Zhang H, Chang Y, Wang Y, Liu L, Zhu Y, Xu J, Xu L, Wang Z. Latency-associated peptide identifies therapeutically resistant muscle-invasive bladder cancer with poor prognosis. Cancer Immunol Immunother 2021. [PMID: 34152439 DOI: 10.1007/s00262-021-02987-4] [Reference Citation Analysis]
87 Wu Z, Guan Q, Han X, Liu X, Li L, Qiu L, Qian Z, Zhou S, Wang X, Zhang H. A novel prognostic signature based on immune-related genes of diffuse large B-cell lymphoma. Aging (Albany NY) 2021;13:22947-62. [PMID: 34610582 DOI: 10.18632/aging.203587] [Reference Citation Analysis]
88 Wharton KA Jr, Wood D, Manesse M, Maclean KH, Leiss F, Zuraw A. Tissue Multiplex Analyte Detection in Anatomic Pathology - Pathways to Clinical Implementation. Front Mol Biosci 2021;8:672531. [PMID: 34386519 DOI: 10.3389/fmolb.2021.672531] [Reference Citation Analysis]
89 Song YJ, Xu Y, Deng C, Zhu X, Fu J, Chen H, Lu J, Xu H, Song G, Tang Q, Wang J. Gene Expression Classifier Reveals Prognostic Osteosarcoma Microenvironment Molecular Subtypes. Front Immunol 2021;12:623762. [PMID: 33959121 DOI: 10.3389/fimmu.2021.623762] [Reference Citation Analysis]
90 Morand GB, Diaconescu A, Ibrahim I, Lamarche G, Ruas JS, Dalfen J, Hier MP, Alaoui-Jamali MA, Maschietto M, da Silva SD. Molecular prognostic indicators in HPV-positive oropharyngeal cancer: an updated review. Clin Exp Metastasis 2022. [PMID: 35084607 DOI: 10.1007/s10585-022-10148-9] [Reference Citation Analysis]
91 Kuksin M, Morel D, Aglave M, Danlos FX, Marabelle A, Zinovyev A, Gautheret D, Verlingue L. Applications of single-cell and bulk RNA sequencing in onco-immunology. Eur J Cancer 2021;149:193-210. [PMID: 33866228 DOI: 10.1016/j.ejca.2021.03.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
92 Richardson JR, Schöllhorn A, Gouttefangeas C, Schuhmacher J. CD4+ T Cells: Multitasking Cells in the Duty of Cancer Immunotherapy. Cancers (Basel) 2021;13:596. [PMID: 33546283 DOI: 10.3390/cancers13040596] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
93 He X, Gu Y, Cao Y, Hu B, Fang H, Fei Y, Lv K, Liu X, Wang J, Lin C, Liu H, Zhang H, Li H, Li R, He H, Xu J. Impact of intratumoural CD73 expression on prognosis and therapeutic response in patients with gastric cancer. Eur J Cancer 2021;157:114-23. [PMID: 34508993 DOI: 10.1016/j.ejca.2021.08.006] [Reference Citation Analysis]
94 Badia-Ramentol J, Linares J, Gómez-Llonin A, Calon A. Minimal Residual Disease, Metastasis and Immunity. Biomolecules 2021;11:130. [PMID: 33498251 DOI: 10.3390/biom11020130] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
95 Zeng D, Wu J, Luo H, Li Y, Xiao J, Peng J, Ye Z, Zhou R, Yu Y, Wang G, Huang N, Wu J, Rong X, Sun L, Sun H, Qiu W, Xue Y, Bin J, Liao Y, Li N, Shi M, Kim KM, Liao W. Tumor microenvironment evaluation promotes precise checkpoint immunotherapy of advanced gastric cancer. J Immunother Cancer 2021;9:e002467. [PMID: 34376552 DOI: 10.1136/jitc-2021-002467] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
96 Lv W, Tan Y, Zhao C, Wang Y, Wu M, Wu Y, Ren Y, Zhang Q. Identification of pyroptosis-related lncRNAs for constructing a prognostic model and their correlation with immune infiltration in breast cancer. J Cell Mol Med 2021;25:10403-17. [PMID: 34632690 DOI: 10.1111/jcmm.16969] [Reference Citation Analysis]
97 Li L, Lu G, Liu Y, Gong L, Zheng X, Zheng H, Gu W, Yang L. Low Infiltration of CD8+ PD-L1+ T Cells and M2 Macrophages Predicts Improved Clinical Outcomes After Immune Checkpoint Inhibitor Therapy in Non-Small Cell Lung Carcinoma. Front Oncol 2021;11:658690. [PMID: 34150625 DOI: 10.3389/fonc.2021.658690] [Reference Citation Analysis]
98 Wu YJ, Nai AT, He GC, Xiao F, Li ZM, Tang SY, Liu YP, Ai XH. DPYSL2 as potential diagnostic and prognostic biomarker linked to immune infiltration in lung adenocarcinoma. World J Surg Oncol 2021;19:274. [PMID: 34517904 DOI: 10.1186/s12957-021-02379-z] [Reference Citation Analysis]
99 Bezombes C, Pérez-Galán P. Immunotherapies in Non-Hodgkin's Lymphoma. Cancers (Basel) 2021;13:3625. [PMID: 34298838 DOI: 10.3390/cancers13143625] [Reference Citation Analysis]
100 Rocha D, García IA, González Montoro A, Llera A, Prato L, Girotti MR, Soria G, Fernández EA. Pan-Cancer Molecular Patterns and Biological Implications Associated with a Tumor-Specific Molecular Signature. Cells 2020;10:E45. [PMID: 33396205 DOI: 10.3390/cells10010045] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
101 Fang Y, Wang Y, Zeng D, Zhi S, Shu T, Huang N, Zheng S, Wu J, Liu Y, Huang G, Xue Y, Bin J, Liao Y, Shi M, Liao W. Comprehensive analyses reveal TKI-induced remodeling of the tumor immune microenvironment in EGFR/ALK-positive non-small-cell lung cancer. Oncoimmunology 2021;10:1951019. [PMID: 34345533 DOI: 10.1080/2162402X.2021.1951019] [Reference Citation Analysis]
102 Charpentier M, Spada S, Vannest S, Demaria S. Radiation therapy-induced remodeling of the tumor immune microenvironment. Seminars in Cancer Biology 2022. [DOI: 10.1016/j.semcancer.2022.04.003] [Reference Citation Analysis]
103 Liu Y, Han M, Li J, Zeng S, Ye Q, Yin Z, Liu S, Zou X. An Analysis Regarding the Association Between Connexins and Colorectal Cancer (CRC) Tumor Microenvironment. JIR 2022;Volume 15:2461-76. [DOI: 10.2147/jir.s361362] [Reference Citation Analysis]
104 Zhou H, Lei PJ, Padera TP. Progression of Metastasis through Lymphatic System. Cells 2021;10:627. [PMID: 33808959 DOI: 10.3390/cells10030627] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
105 Akeus P, Szeponik L, Langenes V, Karlsson V, Sundström P, Bexe-Lindskog E, Tallon C, Slusher BS, Quiding-Järbrink M. Regulatory T cells reduce endothelial neutral sphingomyelinase 2 to prevent T-cell migration into tumors. Eur J Immunol 2021;51:2317-29. [PMID: 34272885 DOI: 10.1002/eji.202149208] [Reference Citation Analysis]
106 Briukhovetska D, Dörr J, Endres S, Libby P, Dinarello CA, Kobold S. Interleukins in cancer: from biology to therapy. Nat Rev Cancer 2021;21:481-99. [PMID: 34083781 DOI: 10.1038/s41568-021-00363-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
107 He W, Wang B, He J, Zhao Y, Zhao W. SSR4 as a prognostic biomarker and related with immune infiltration cells in colon adenocarcinoma. Expert Rev Mol Diagn 2021;:1-9. [PMID: 34904499 DOI: 10.1080/14737159.2022.2019015] [Reference Citation Analysis]
108 Gao R, He B, Huang Q, Wang Z, Yan M, Wing-Fai Lam E, Lin S, Wang B, Liu Q. Cancer cell immune mimicry delineates onco-immunologic modulation. iScience 2021;24:103133. [PMID: 34632332 DOI: 10.1016/j.isci.2021.103133] [Reference Citation Analysis]
109 Yuan D, Wei Z, Wang Y, Cheng F, Zeng Y, Yang L, Zhang S, Li J, Tang R. DNA Methylation Regulator-Meditated Modification Patterns Define the Distinct Tumor Microenvironment in Lung Adenocarcinoma. Front Oncol 2021;11:734873. [PMID: 34552879 DOI: 10.3389/fonc.2021.734873] [Reference Citation Analysis]
110 Zhao L, Luo B, Wang L, Chen W, Jiang M, Zhang N. Pan-cancer analysis reveals the roles of XPO1 in predicting prognosis and tumorigenesis. Transl Cancer Res 2021;10:4664-79. [PMID: 35116322 DOI: 10.21037/tcr-21-1646] [Reference Citation Analysis]
111 Too NSH, Ho NCW, Adine C, Iyer NG, Fong ELS. Hot or cold: Bioengineering immune contextures into in vitro patient-derived tumor models. Adv Drug Deliv Rev 2021;175:113791. [PMID: 33965462 DOI: 10.1016/j.addr.2021.05.001] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
112 Baertsch MA, Nolan GP, Hickey JW. Multicellular modules as clinical diagnostic and therapeutic targets. Trends Cancer 2021:S2405-8033(21)00230-2. [PMID: 34872889 DOI: 10.1016/j.trecan.2021.11.004] [Reference Citation Analysis]
113 Seifert L, Plesca I, Müller L, Sommer U, Heiduk M, von Renesse J, Digomann D, Glück J, Klimova A, Weitz J, Schmitz M, Seifert AM. LAG-3-Expressing Tumor-Infiltrating T Cells Are Associated with Reduced Disease-Free Survival in Pancreatic Cancer. Cancers (Basel) 2021;13:1297. [PMID: 33803936 DOI: 10.3390/cancers13061297] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
114 Zou M, Wu H, Zhou M, Xiao F, Abudushalamu G, Yao Y, Zhao F, Gao W, Yan X, Fan X, Wu G. High expression of CLEC10A in head and neck squamous cell carcinoma indicates favorable prognosis and high‐level immune infiltration status. Cellular Immunology 2021. [DOI: 10.1016/j.cellimm.2021.104472] [Reference Citation Analysis]
115 Liu W, Zhang J, Xie T, Huang X, Wang B, Tian Y, Yuan Y. C1QTNF6 is a Prognostic Biomarker and Related to Immune Infiltration and Drug Sensitivity: A Pan-Cancer Analysis. Front Pharmacol 2022;13:855485. [DOI: 10.3389/fphar.2022.855485] [Reference Citation Analysis]
116 Yang X, Yan J, Jiang Y, Wang Y. An immune-related model based on INHBA, JAG2 and CCL19 to predict the prognoses of colon cancer patients. Cancer Cell Int 2021;21:299. [PMID: 34103052 DOI: 10.1186/s12935-021-02000-z] [Reference Citation Analysis]
117 Kwon JTW, Bryant RJ, Parkes EE. The tumor microenvironment and immune responses in prostate cancer patients. Endocr Relat Cancer 2021;28:T95-T107. [PMID: 34128831 DOI: 10.1530/ERC-21-0149] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
118 Pan B, Yang M, Wei X, Li W, Wang K, Yang M, Lu D, Wang R, Cen B, Xu X. Interleukin-2 inducible T-cell kinase: a potential prognostic biomarker and tumor microenvironment remodeling indicator for hepatocellular carcinoma. Aging (Albany NY) 2021;13:18620-44. [PMID: 34282055 DOI: 10.18632/aging.203306] [Reference Citation Analysis]
119 Locy H, Verhulst S, Cools W, Waelput W, Brock S, Cras L, Schiettecatte A, Jonckheere J, van Grunsven LA, Vanhoeij M, Thielemans K, Breckpot K. Assessing Tumor-Infiltrating Lymphocytes in Breast Cancer: A Proposal for Combining Immunohistochemistry and Gene Expression Analysis to Refine Scoring. Front Immunol 2022;13:794175. [DOI: 10.3389/fimmu.2022.794175] [Reference Citation Analysis]
120 Yanai Y, Kosaka T, Mikami S, Hongo H, Yasumizu Y, Takeda T, Matsumoto K, Miyauchi J, Kitano S, Oya M. CD8-positive T cells and CD204-positive M2-like macrophages predict postoperative prognosis of very high-risk prostate cancer. Sci Rep 2021;11:22495. [PMID: 34795362 DOI: 10.1038/s41598-021-01900-4] [Reference Citation Analysis]
121 Balta E, Wabnitz GH, Samstag Y. Hijacked Immune Cells in the Tumor Microenvironment: Molecular Mechanisms of Immunosuppression and Cues to Improve T Cell-Based Immunotherapy of Solid Tumors. Int J Mol Sci 2021;22:5736. [PMID: 34072260 DOI: 10.3390/ijms22115736] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
122 Powles T, Sridhar SS, Loriot Y, Bellmunt J, Mu XJ, Ching KA, Pu J, Sternberg CN, Petrylak DP, Tambaro R, Dourthe LM, Alvarez-Fernandez C, Aarts M, di Pietro A, Grivas P, Davis CB. Avelumab maintenance in advanced urothelial carcinoma: biomarker analysis of the phase 3 JAVELIN Bladder 100 trial. Nat Med 2021;27:2200-11. [PMID: 34893775 DOI: 10.1038/s41591-021-01579-0] [Reference Citation Analysis]
123 Wei X, Wang Y, Ji C, Luan J, Yao L, Zhang X, Wang S, Yao B, Qin C, Song N. Genomic Instability Promotes the Progression of Clear Cell Renal Cell Carcinoma Through Influencing the Immune Microenvironment. Front Genet 2021;12:706661. [PMID: 34712264 DOI: 10.3389/fgene.2021.706661] [Reference Citation Analysis]
124 Dong M, Chen J, Deng Y, Zhang D, Dong L, Sun D. H2AFZ Is a Prognostic Biomarker Correlated to TP53 Mutation and Immune Infiltration in Hepatocellular Carcinoma. Front Oncol 2021;11:701736. [PMID: 34760688 DOI: 10.3389/fonc.2021.701736] [Reference Citation Analysis]
125 Liu R, Yang F, Yin JY, Liu YZ, Zhang W, Zhou HH. Influence of Tumor Immune Infiltration on Immune Checkpoint Inhibitor Therapeutic Efficacy: A Computational Retrospective Study. Front Immunol 2021;12:685370. [PMID: 34220837 DOI: 10.3389/fimmu.2021.685370] [Reference Citation Analysis]
126 Small S, Numan Y, Platanias LC. Innate Immune Mechanisms and Immunotherapy of Myeloid Malignancies. Biomedicines 2021;9:1631. [PMID: 34829860 DOI: 10.3390/biomedicines9111631] [Reference Citation Analysis]
127 Li X, Li Z, Liu P, Ai S, Sun F, Hu Q, Dong Y, Xia X, Guan W, Liu S. Novel CircRNAs in Hub ceRNA Axis Regulate Gastric Cancer Prognosis and Microenvironment. Front Med (Lausanne) 2021;8:771206. [PMID: 34820403 DOI: 10.3389/fmed.2021.771206] [Reference Citation Analysis]
128 Sierra JM, Secchiari F, Nuñez SY, Iraolagoitia XLR, Ziblat A, Friedrich AD, Regge MV, Santilli MC, Torres NI, Gantov M, Trotta A, Ameri C, Vitagliano G, Pita HR, Rico L, Rovegno A, Richards N, Domaica CI, Zwirner NW, Fuertes MB. Tumor-Experienced Human NK Cells Express High Levels of PD-L1 and Inhibit CD8+ T Cell Proliferation. Front Immunol 2021;12:745939. [PMID: 34616407 DOI: 10.3389/fimmu.2021.745939] [Reference Citation Analysis]
129 Cao K, Ma T, Ling X, Liu M, Jiang X, Ma K, Zhu J, Ma J. Development of immune gene pair-based signature predictive of prognosis and immunotherapy in esophageal cancer. Ann Transl Med 2021;9:1591. [PMID: 34790797 DOI: 10.21037/atm-21-5217] [Reference Citation Analysis]
130 Apollonio B, Ioannou N, Papazoglou D, Ramsay AG. Understanding the Immune-Stroma Microenvironment in B Cell Malignancies for Effective Immunotherapy. Front Oncol 2021;11:626818. [PMID: 33842331 DOI: 10.3389/fonc.2021.626818] [Reference Citation Analysis]
131 Zhang H, Wu J, Liu Z, Gao J, Li S, Gao D. SPARCL1 Is a Novel Prognostic Biomarker and Correlates with Tumor Microenvironment in Colorectal Cancer. BioMed Research International 2022;2022:1-13. [DOI: 10.1155/2022/1398268] [Reference Citation Analysis]
132 Xiao H, Zhang J, Wang K, Song K, Zheng H, Yang J, Li K, Yuan R, Zhao W, Hui Y. A Cancer-Specific Qualitative Method for Estimating the Proportion of Tumor-Infiltrating Immune Cells. Front Immunol 2021;12:672031. [PMID: 34054849 DOI: 10.3389/fimmu.2021.672031] [Reference Citation Analysis]
133 Chen J, Wang Y, Zhang W, Zhao D, Zhang L, Zhang J, Fan J, Zhan Q. NOX5 mediates the crosstalk between tumor cells and cancer-associated fibroblasts via regulating cytokine network. Clin Transl Med 2021;11:e472. [PMID: 34459125 DOI: 10.1002/ctm2.472] [Reference Citation Analysis]
134 Huang Z, Li B, Guo Y, Wu L, Kou F, Yang L. Signatures of Multi-Omics Reveal Distinct Tumor Immune Microenvironment Contributing to Immunotherapy in Lung Adenocarcinoma. Front Immunol 2021;12:723172. [PMID: 34539658 DOI: 10.3389/fimmu.2021.723172] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
135 Ikarashi D, Okimoto T, Shukuya T, Onagi H, Hayashi T, Sinicropi-Yao SL, Amann JM, Nakatsura T, Kitano S, Carbone DP. Comparison of Tumor Microenvironments Between Primary Tumors and Brain Metastases in Patients With NSCLC. JTO Clin Res Rep 2021;2:100230. [PMID: 34647108 DOI: 10.1016/j.jtocrr.2021.100230] [Reference Citation Analysis]
136 Yang Y, Wu M, Cao D, Yang C, Jin J, Wu L, Hong X, Li W, Lu L, Li J, Wang X, Meng X, Zhang Z, Cheng J, Ye Y, Xiao H, Yu J, Deng L. ZBP1-MLKL necroptotic signaling potentiates radiation-induced antitumor immunity via intratumoral STING pathway activation. Sci Adv 2021;7:eabf6290. [PMID: 34613770 DOI: 10.1126/sciadv.abf6290] [Reference Citation Analysis]
137 Venkatraman S, Balasubramanian B, Pongchaikul P, Tohtong R, Chutipongtanate S. Molecularly Guided Drug Repurposing for Cholangiocarcinoma: An Integrative Bioinformatic Approach. Genes 2022;13:271. [DOI: 10.3390/genes13020271] [Reference Citation Analysis]
138 Qi J, Zhang J, Ge X, Wang X, Xu L, Liu N, Zhao L, Wang P. The Addition of Peripheral Blood Inflammatory Indexes to Nomogram Improves the Predictive Accuracy of Survival in Limited-Stage Small Cell Lung Cancer Patients. Front Oncol 2021;11:713014. [PMID: 34692490 DOI: 10.3389/fonc.2021.713014] [Reference Citation Analysis]
139 Bindea G, Mlecnik B, Galon J. Tumor spread or siege immunity: dissemination to distant metastasis or not. Oncoimmunology 2021;10:1919377. [PMID: 33996269 DOI: 10.1080/2162402X.2021.1919377] [Reference Citation Analysis]
140 Li X, Yang Y, Huang Q, Deng Y, Guo F, Wang G, Liu M. Crosstalk Between the Tumor Microenvironment and Cancer Cells: A Promising Predictive Biomarker for Immune Checkpoint Inhibitors. Front Cell Dev Biol 2021;9:738373. [PMID: 34692696 DOI: 10.3389/fcell.2021.738373] [Reference Citation Analysis]
141 Aroca-Siendones MI, Moreno-SanJuan S, Puentes-Pardo JD, Verbeni M, Arnedo J, Escudero-Feliu J, García-Costela M, García-Robles A, Carazo Á, León J. Core Circadian Clock Proteins as Biomarkers of Progression in Colorectal Cancer. Biomedicines 2021;9:967. [PMID: 34440171 DOI: 10.3390/biomedicines9080967] [Reference Citation Analysis]
142 Wang G, Qi W, Shen L, Wang S, Xiao R, Li W, Zhang Y, Bian X, Sun L, Qiu W. The pattern of alternative splicing in lung adenocarcinoma shows novel events correlated with tumorigenesis and immune microenvironment. BMC Pulm Med 2021;21:400. [PMID: 34872548 DOI: 10.1186/s12890-021-01776-0] [Reference Citation Analysis]
143 Tittarelli A. Connexin channels modulation in pathophysiology and treatment of immune and inflammatory disorders. Biochim Biophys Acta Mol Basis Dis 2021;1867:166258. [PMID: 34450245 DOI: 10.1016/j.bbadis.2021.166258] [Reference Citation Analysis]
144 Montironi C, Castet F, Haber PK, Pinyol R, Torres-Martin M, Torrens Fontanals L, Mesropian A, Wang H, Puigvehi M, Maeda M, Leow WQ, Harrod E, Taik P, Chinburen J, Taivanbaatar E, Chinbold E, Solé Arqués M, Donovan M, Thung S, Neely J, Mazzaferro V, Anderson J, Roayaie S, Schwartz M, Villanueva A, Friedman SL, Uzilov A, Sia D, Llovet JM. Inflamed and non-inflamed classes of HCC: a revised immunogenomic classification. Gut 2022:gutjnl-2021-325918. [PMID: 35197323 DOI: 10.1136/gutjnl-2021-325918] [Reference Citation Analysis]
145 Yamazaki T, Bravo-San Pedro JM, Galluzzi L, Kroemer G, Pietrocola F. Autophagy in the cancer-immunity dialogue. Adv Drug Deliv Rev 2021;169:40-50. [PMID: 33301821 DOI: 10.1016/j.addr.2020.12.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
146 Li X, Wang Y, Wu W, Xiang J, Qi L, Wang N, Wang M, Yu H, Ding X. A Novel Risk Score Model Based on Eleven Extracellular Matrix-Related Genes for Predicting Overall Survival of Glioma Patients. Journal of Oncology 2022;2022:1-20. [DOI: 10.1155/2022/4966820] [Reference Citation Analysis]
147 Nassif EF, Thibault C, Oudard S, Galon J. Precision immunity: Immunoscore and neoadjuvant treatment in bladder cancer. Oncoimmunology 2021;10:1888488. [PMID: 33659099 DOI: 10.1080/2162402X.2021.1888488] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
148 Denti V, Mahajneh A, Capitoli G, Clerici F, Piga I, Pagani L, Chinello C, Bolognesi MM, Paglia G, Galimberti S, Magni F, Smith A. Lipidomic Typing of Colorectal Cancer Tissue Containing Tumour-Infiltrating Lymphocytes by MALDI Mass Spectrometry Imaging. Metabolites 2021;11:599. [PMID: 34564418 DOI: 10.3390/metabo11090599] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
149 Kanani A, Veen T, Søreide K. Neoadjuvant immunotherapy in primary and metastatic colorectal cancer. Br J Surg 2021:znab342. [PMID: 34694371 DOI: 10.1093/bjs/znab342] [Reference Citation Analysis]
150 Zhou P, Lu Y, Xun Y, Xu J, Liu C, Xia Q, Lu J, Wang S, Hu J. Ubiquitin Modification Patterns of Clear Cell Renal Cell Carcinoma and the Ubiquitin Score to Aid Immunotherapy and Targeted Therapy. Front Cell Dev Biol 2021;9:659294. [PMID: 34055790 DOI: 10.3389/fcell.2021.659294] [Reference Citation Analysis]
151 Guo H, Li W, Qian L, Cui J. Clinical challenges in neoadjuvant immunotherapy for non-small cell lung cancer. Chin J Cancer Res 2021;33:203-15. [PMID: 34158740 DOI: 10.21147/j.issn.1000-9604.2021.02.08] [Reference Citation Analysis]
152 Feng F, Shen B, Mou X, Li Y, Li H. Large-scale pharmacogenomic studies and drug response prediction for personalized cancer medicine. J Genet Genomics 2021:S1673-8527(21)00084-9. [PMID: 34023295 DOI: 10.1016/j.jgg.2021.03.007] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
153 Shen DS, Yan C, Chen KH, Li L, Qu S, Zhu XD. A Nomogram Based on Circulating CD4+ T Lymphocytes and Lactate Dehydrogenase to Predict Distant Metastasis in Patients with Nasopharyngeal Carcinoma. J Inflamm Res 2021;14:6707-18. [PMID: 34916820 DOI: 10.2147/JIR.S341897] [Reference Citation Analysis]
154 Lopès A, Goldszmid RS. Microbes-myeloid-tumor: a colonic triad against T cells. Immunity 2022;55:582-5. [PMID: 35417671 DOI: 10.1016/j.immuni.2022.03.011] [Reference Citation Analysis]
155 Lonie JM, Barbour AP, Dolcetti R. Understanding the immuno-biology of oesophageal adenocarcinoma: Towards improved therapeutic approaches. Cancer Treat Rev 2021;98:102219. [PMID: 33993033 DOI: 10.1016/j.ctrv.2021.102219] [Reference Citation Analysis]
156 Ducoin K, Oger R, Bilonda Mutala L, Deleine C, Jouand N, Desfrançois J, Podevin J, Duchalais E, Cruard J, Benlalam H, Labarrière N, Bossard C, Jarry A, Gervois-segain N. Targeting NKG2A to boost anti-tumor CD8 T-cell responses in human colorectal cancer. OncoImmunology 2022;11:2046931. [DOI: 10.1080/2162402x.2022.2046931] [Reference Citation Analysis]
157 Petroni G, Buqué A, Coussens LM, Galluzzi L. Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment. Nat Rev Drug Discov 2022. [PMID: 35292771 DOI: 10.1038/s41573-022-00415-5] [Reference Citation Analysis]
158 Pereira C, Parolo C, Idili A, Gomis RR, Rodrigues L, Sales G, Merkoçi A. Paper-based biosensors for cancer diagnostics. Trends in Chemistry 2022. [DOI: 10.1016/j.trechm.2022.03.005] [Reference Citation Analysis]
159 Baram T, Rubinstein-Achiasaf L, Ben-Yaakov H, Ben-Baruch A. Inflammation-Driven Breast Tumor Cell Plasticity: Stemness/EMT, Therapy Resistance and Dormancy. Front Oncol 2020;10:614468. [PMID: 33585241 DOI: 10.3389/fonc.2020.614468] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
160 Guan R, Lyu Q, Lin A, Liang J, Ding W, Cao M, Luo P, Zhang J. Influence of Different Age Cutoff Points on the Prediction of Prognosis of Cancer Patients Receiving ICIs and Potential Mechanistic Exploration. Front Oncol 2021;11:670927. [PMID: 34249711 DOI: 10.3389/fonc.2021.670927] [Reference Citation Analysis]
161 Kießler M, Plesca I, Sommer U, Wehner R, Wilczkowski F, Müller L, Tunger A, Lai X, Rentsch A, Peuker K, Zeissig S, Seifert AM, Seifert L, Weitz J, Bachmann M, Bornhäuser M, Aust D, Baretton G, Schmitz M. Tumor-infiltrating plasmacytoid dendritic cells are associated with survival in human colon cancer. J Immunother Cancer 2021;9:e001813. [PMID: 33762320 DOI: 10.1136/jitc-2020-001813] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
162 Zhang Y, Zhang R, Liang F, Zhang L, Liang X. Identification of Metabolism-Associated Prostate Cancer Subtypes and Construction of a Prognostic Risk Model. Front Oncol 2020;10:598801. [PMID: 33324566 DOI: 10.3389/fonc.2020.598801] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
163 Wang D, Ao J, Xiong Y, Zhang X, Zhang W. Systematic Analysis of Stress Granule Regulators-Associated Molecular Subtypes Predicts Drug Response, Immune Response, and Prognosis in Non-Small Cell Lung Cancer. Front Cell Dev Biol 2022;10:868918. [DOI: 10.3389/fcell.2022.868918] [Reference Citation Analysis]
164 Goc J, Lv M, Bessman NJ, Flamar AL, Sahota S, Suzuki H, Teng F, Putzel GG, Eberl G, Withers DR, Arthur JC, Shah MA, Sonnenberg GF; JRI Live Cell Bank. Dysregulation of ILC3s unleashes progression and immunotherapy resistance in colon cancer. Cell 2021;184:5015-5030.e16. [PMID: 34407392 DOI: 10.1016/j.cell.2021.07.029] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
165 Arnouk S, De Groof TW, Van Ginderachter JA. Imaging and therapeutic targeting of the tumor immune microenvironment with biologics. Advanced Drug Delivery Reviews 2022. [DOI: 10.1016/j.addr.2022.114239] [Reference Citation Analysis]
166 El Sissy C, Kirilovsky A, Zeitoun G, Marliot F, Haicheur N, Lagorce-Pagès C, Galon J, Pagès F. Therapeutic Implications of the Immunoscore in Patients with Colorectal Cancer. Cancers (Basel) 2021;13:1281. [PMID: 33805758 DOI: 10.3390/cancers13061281] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
167 Russo M, Nastasi C. Targeting the Tumor Microenvironment: A Close Up of Tumor-Associated Macrophages and Neutrophils. Front Oncol 2022;12:871513. [DOI: 10.3389/fonc.2022.871513] [Reference Citation Analysis]
168 Chan DKH, Buczacki SJA. Tumour heterogeneity and evolutionary dynamics in colorectal cancer. Oncogenesis 2021;10:53. [PMID: 34272358 DOI: 10.1038/s41389-021-00342-x] [Reference Citation Analysis]
169 Xiao Z, Nie K, Han T, Cheng L, Zhang Z, Peng W, Shi D. Development and Validation of a TNF Family-Based Signature for Predicting Prognosis, Tumor Immune Characteristics, and Immunotherapy Response in Colorectal Cancer Patients. J Immunol Res 2021;2021:6439975. [PMID: 34541005 DOI: 10.1155/2021/6439975] [Reference Citation Analysis]
170 Cancian P, Cortese N, Donadon M, Di Maio M, Soldani C, Marchesi F, Savevski V, Santambrogio MD, Cerina L, Laino ME, Torzilli G, Mantovani A, Terracciano L, Roncalli M, Di Tommaso L. Development of a Deep-Learning Pipeline to Recognize and Characterize Macrophages in Colo-Rectal Liver Metastasis. Cancers (Basel) 2021;13:3313. [PMID: 34282750 DOI: 10.3390/cancers13133313] [Reference Citation Analysis]
171 Zou W, Zhou ML, Zhang LY, Yang JN, Yang W, Wang YQ, Yi YX, Li GC, Zhang Z. Immune Score Predicts Outcomes of Gastric Cancer Patients Treated with Adjuvant Chemoradiotherapy. J Oncol 2021;2021:9344124. [PMID: 34987582 DOI: 10.1155/2021/9344124] [Reference Citation Analysis]
172 Campana LG, Peric B, Mascherini M, Spina R, Kunte C, Kis E, Rozsa P, Quaglino P, Jones RP, Clover AJP, Curatolo P, Giorgione R, Cemazar M, Terlizzi F, Bosnjak M, Sersa G. Combination of Pembrolizumab with Electrochemotherapy in Cutaneous Metastases from Melanoma: A Comparative Retrospective Study from the InspECT and Slovenian Cancer Registry. Cancers (Basel) 2021;13:4289. [PMID: 34503099 DOI: 10.3390/cancers13174289] [Reference Citation Analysis]
173 Desai R, Coxon AT, Dunn GP. Therapeutic applications of the cancer immunoediting hypothesis. Semin Cancer Biol 2021:S1044-579X(21)00052-3. [PMID: 33711414 DOI: 10.1016/j.semcancer.2021.03.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
174 Cai H, Feng Y, Fan P, Guo Y, Kuerban G, Chang C, Yao X, Peng Y, Wang R. HPV16 E6-specific T cell response and HLA-A alleles are related to the prognosis of patients with cervical cancer. Infect Agent Cancer 2021;16:61. [PMID: 34530896 DOI: 10.1186/s13027-021-00395-y] [Reference Citation Analysis]
175 Eckstein M, Lieb V, Jung R, Sikic D, Weigelt K, Stöhr R, Geppert C, Weyerer V, Bertz S, Serrero G, Yue B, Hartmann A, Wullich B, Taubert H, Wach S. Combination of GP88 Expression in Tumor Cells and Tumor-Infiltrating Immune Cells Is an Independent Prognostic Factor for Bladder Cancer Patients. Cells 2021;10:1796. [PMID: 34359965 DOI: 10.3390/cells10071796] [Reference Citation Analysis]
176 Hu ZW, Chen L, Ma RQ, Wei FQ, Wen YH, Zeng XL, Sun W, Wen WP. Comprehensive analysis of ferritin subunits expression and positive correlations with tumor-associated macrophages and T regulatory cells infiltration in most solid tumors. Aging (Albany NY) 2021;13:11491-506. [PMID: 33864445 DOI: 10.18632/aging.202841] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
177 Nakamura T, Kawakami K, Nomura M, Sato Y, Hyodo M, Hatakeyama H, Hayakawa Y, Harashima H. Combined nano cancer immunotherapy based on immune status in a tumor microenvironment. Journal of Controlled Release 2022. [DOI: 10.1016/j.jconrel.2022.03.026] [Reference Citation Analysis]
178 Zhao Q, Cai Q, Yu S, Ji J, Zhu Z, Yan C, Zhang J. Combinatorial Analysis of AT-Rich Interaction Domain 1A and CD47 in Gastric Cancer Patients Reveals Markers of Prognosis. Front Cell Dev Biol 2021;9:745120. [PMID: 34805154 DOI: 10.3389/fcell.2021.745120] [Reference Citation Analysis]
179 Li Q, Yao L, Lin Z, Li F, Xie D, Li C, Zhan W, Lin W, Huang L, Wu S, Zhou H. Identification of Prognostic Model Based on Immune-Related LncRNAs in Stage I-III Non-Small Cell Lung Cancer. Front Oncol 2021;11:706616. [PMID: 34745939 DOI: 10.3389/fonc.2021.706616] [Reference Citation Analysis]
180 Faget J, Peters S, Quantin X, Meylan E, Bonnefoy N. Neutrophils in the era of immune checkpoint blockade. J Immunother Cancer 2021;9:e002242. [PMID: 34301813 DOI: 10.1136/jitc-2020-002242] [Reference Citation Analysis]
181 Bruschini S, Pallocca M, Sperandio E, D'Ambrosio L, Ascenzi F, De Vitis C, Salvati V, Esposito A, Di Martino S, De Nicola F, Paolini F, Fattore L, Alessandrini G, Facciolo F, Foddai ML, Bassi M, Venuta F, D'Ascanio M, Ricci A, D' Andrilli A, Napoli C, Aurisicchio L, Fanciulli M, Rendina EA, Ciliberto G, Mancini R. Deconvolution of malignant pleural effusions immune landscape unravels a novel macrophage signature associated with worse clinical outcome in lung adenocarcinoma patients. J Immunother Cancer 2022;10:e004239. [PMID: 35584864 DOI: 10.1136/jitc-2021-004239] [Reference Citation Analysis]
182 Du M, Cai YM, Yin YL, Xiao L, Ji Y. Evaluating tumor-infiltrating lymphocytes in hepatocellular carcinoma using hematoxylin and eosin-stained tumor sections. World J Clin Cases 2022; 10(3): 856-869 [DOI: 10.12998/wjcc.v10.i3.856] [Reference Citation Analysis]
183 Xu LQ, Yao LJ, Jiang D, Zhou LJ, Chen M, Liao WZ, Zou WH, Peng HJ. A uracil auxotroph Toxoplasma gondii exerting immunomodulation to inhibit breast cancer growth and metastasis. Parasit Vectors 2021;14:601. [PMID: 34895326 DOI: 10.1186/s13071-021-05032-6] [Reference Citation Analysis]
184 Persano S, Vicini F, Poggi A, Fernandez JLC, Rizzo GMR, Gavilán H, Silvestri N, Pellegrino T. Elucidating the Innate Immunological Effects of Mild Magnetic Hyperthermia on U87 Human Glioblastoma Cells: An In Vitro Study. Pharmaceutics 2021;13:1668. [PMID: 34683961 DOI: 10.3390/pharmaceutics13101668] [Reference Citation Analysis]
185 Yan G, An Y, Xu B, Wang N, Sun X, Sun M. Potential Impact of ALKBH5 and YTHDF1 on Tumor Immunity in Colon Adenocarcinoma. Front Oncol 2021;11:670490. [PMID: 34079761 DOI: 10.3389/fonc.2021.670490] [Reference Citation Analysis]
186 Hersey S, Keller S, Mathews J, King L, Bandukwala A, Berisha F, Birchler M, Bower J, Clausen V, Duarte J, Garofolo F, Hopper S, Kar S, Mabrouk O, Marshall JC, McGuire K, Naughton M, Saito Y, Schuhmann I, Sperinde G, Teixeira P, Vitaliti A, Wang YM, Wnek R, Zhang Y, Spitz S, Decman V, Eck S, Estevam J, Goihberg P, Alcaide EG, Gonneau C, Hedrick MN, Hopkins G, Junker F, Nuti S, Sommer U, Standifer N, Stevens C, Stevens E, Hendricks C, Wadhwa M, Torri A, Ma M, Harris S, Kumar S, Partridge MA, Caiazzo T, Chilewski S, Cludts I, Coble K, Gorovits B, Grimaldi C, Jordan G, Kamerud J, Leary B, Liang M, Lim H, Mayer A, O'Connor E, Palackal N, Poetzl J, Prior S, Abhari MR, Savoie N, Soo C, Ware M, Wu B, Xu Y, Yang TY, Zoghbi J. 2021 White Paper on Recent Issues in Bioanalysis: ISR for Biomarkers, Liquid Biopsies, Spectral Cytometry, Inhalation/Oral & Multispecific Biotherapeutics, Accuracy/LLOQ for Flow Cytometry (Part 2 - Recommendations on Biomarkers/CDx Assays Development & Validation, Cytometry Validation & Innovation, Biotherapeutics PK LBA Regulated Bioanalysis, Critical Reagents & Positive Controls Generation). Bioanalysis 2022. [PMID: 35578974 DOI: 10.4155/bio-2022-0080] [Reference Citation Analysis]
187 Mauri G, Vitiello PP, Sogari A, Crisafulli G, Sartore-Bianchi A, Marsoni S, Siena S, Bardelli A. Liquid biopsies to monitor and direct cancer treatment in colorectal cancer. Br J Cancer 2022. [PMID: 35264786 DOI: 10.1038/s41416-022-01769-8] [Reference Citation Analysis]
188 Raskov H, Orhan A, Gaggar S, Gögenur I. Neutrophils and polymorphonuclear myeloid-derived suppressor cells: an emerging battleground in cancer therapy. Oncogenesis 2022;11:22. [PMID: 35504900 DOI: 10.1038/s41389-022-00398-3] [Reference Citation Analysis]
189 Li X, Zhou H, Huang W, Wang X, Meng M, Hou Z, Liao L, Tang W, Xie Y, Wang R, Yu H, Wang L, Zhu H, Wang W, Tan J, Li R. Retrospective analysis of the efficacy of adjuvant cytokine‐induced killer cell immunotherapy combined with chemotherapy in colorectal cancer patients after surgery. Clin & Trans Imm 2022;11. [DOI: 10.1002/cti2.1368] [Reference Citation Analysis]
190 Andreatta M, David FPA, Iseli C, Guex N, Carmona SJ. SPICA: Swiss portal for immune cell analysis. Nucleic Acids Res 2021:gkab1055. [PMID: 34747477 DOI: 10.1093/nar/gkab1055] [Reference Citation Analysis]
191 Lee H, Choi H. Investigating the Clinico-Molecular and Immunological Evolution of Lung Adenocarcinoma Using Pseudotime Analysis. Front Oncol 2022;12:828505. [DOI: 10.3389/fonc.2022.828505] [Reference Citation Analysis]
192 Pan X, Gao A, Lin Z. Fluorescence imaging of tumor immune contexture in immune checkpoint blockade therapy. International Immunopharmacology 2022;106:108617. [DOI: 10.1016/j.intimp.2022.108617] [Reference Citation Analysis]
193 Diao P, Jiang Y, Li Y, Wu X, Li J, Zhou C, Jiang L, Zhang W, Yan E, Zhang P, Ding X, Wu H, Yuan H, Ye J, Song X, Wan L, Wu Y, Jiang H, Wang Y, Cheng J. Immune landscape and subtypes in primary resectable oral squamous cell carcinoma: prognostic significance and predictive of therapeutic response. J Immunother Cancer 2021;9:e002434. [PMID: 34130988 DOI: 10.1136/jitc-2021-002434] [Reference Citation Analysis]
194 Xia S, Gu Y, Zhang H, Fei Y, Cao Y, Fang H, Wang J, Lin C, Zhang H, Li H, He H, Xu J, Li R, Liu H, Zhang W. Immune inactivation by APOBEC3B enrichment predicts response to chemotherapy and survival in gastric cancer. Oncoimmunology 2021;10:1975386. [PMID: 34552824 DOI: 10.1080/2162402X.2021.1975386] [Reference Citation Analysis]
195 Koedijk JB, van der Werf I, Calkoen FG, Nierkens S, Kaspers GJL, Zwaan CM, Heidenreich O. Paving the Way for Immunotherapy in Pediatric Acute Myeloid Leukemia: Current Knowledge and the Way Forward. Cancers (Basel) 2021;13:4364. [PMID: 34503174 DOI: 10.3390/cancers13174364] [Reference Citation Analysis]
196 Wu J, Zhang T, Xiong H, Zeng L, Wang Z, Peng Y, Chen W, Hu X, Su T. Tumor-Infiltrating CD4+ Central Memory T Cells Correlated with Favorable Prognosis in Oral Squamous Cell Carcinoma. J Inflamm Res 2022;15:141-52. [PMID: 35035226 DOI: 10.2147/JIR.S343432] [Reference Citation Analysis]
197 Zhang Z, Mei Y, Hou M. Knockdown RBM15 Inhibits Colorectal Cancer Cell Proliferation and Metastasis Via N6-Methyladenosine (m6A) Modification of MyD88 mRNA. Cancer Biother Radiopharm 2021. [PMID: 34842457 DOI: 10.1089/cbr.2021.0226] [Reference Citation Analysis]
198 Kohlruss M, Ott K, Grosser B, Jesinghaus M, Slotta-Huspenina J, Novotny A, Hapfelmeier A, Schmidt T, Gaida MM, Weichert W, Keller G. Sexual Difference Matters: Females with High Microsatellite Instability Show Increased Survival after Neoadjuvant Chemotherapy in Gastric Cancer. Cancers (Basel) 2021;13:1048. [PMID: 33801374 DOI: 10.3390/cancers13051048] [Reference Citation Analysis]
199 Ren J, Sun J, Li M, Zhang Z, Yang D, Cao H. MAPK Activated Protein Kinase 3 Is a Prognostic-Related Biomarker and Associated With Immune Infiltrates in Glioma. Front Oncol 2021;11:793025. [PMID: 34938665 DOI: 10.3389/fonc.2021.793025] [Reference Citation Analysis]
200 Lu JC, Zhang PF, Huang XY, Guo XJ, Gao C, Zeng HY, Zheng YM, Wang SW, Cai JB, Sun QM, Shi YH, Zhou J, Ke AW, Shi GM, Fan J. Amplification of spatially isolated adenosine pathway by tumor-macrophage interaction induces anti-PD1 resistance in hepatocellular carcinoma. J Hematol Oncol 2021;14:200. [PMID: 34838121 DOI: 10.1186/s13045-021-01207-x] [Reference Citation Analysis]
201 Kohlruss M, Krenauer M, Grosser B, Pfarr N, Jesinghaus M, Slotta-Huspenina J, Novotny A, Hapfelmeier A, Schmidt T, Steiger K, Gaida MM, Reiche M, Bauer L, Ott K, Weichert W, Keller G. Diverse 'just-right' levels of chromosomal instability and their clinical implications in neoadjuvant treated gastric cancer. Br J Cancer 2021. [PMID: 34671125 DOI: 10.1038/s41416-021-01587-4] [Reference Citation Analysis]
202 Yu S, Li X, Zhang J, Wu S. Development of a Novel Immune Infiltration-Based Gene Signature to Predict Prognosis and Immunotherapy Response of Patients With Cervical Cancer. Front Immunol 2021;12:709493. [PMID: 34539641 DOI: 10.3389/fimmu.2021.709493] [Reference Citation Analysis]
203 Van den Eynde M, Mlecnik B, Bindea G, Galon J. Multiverse of immune microenvironment in metastatic colorectal cancer. Oncoimmunology 2020;9:1824316. [PMID: 33457100 DOI: 10.1080/2162402X.2020.1824316] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
204 Aasebø K, Bruun J, Bergsland CH, Nunes L, Eide GE, Pfeiffer P, Dahl O, Glimelius B, Lothe RA, Sorbye H. Prognostic role of tumour-infiltrating lymphocytes and macrophages in relation to MSI, CDX2 and BRAF status: a population-based study of metastatic colorectal cancer patients. Br J Cancer 2021. [PMID: 34671130 DOI: 10.1038/s41416-021-01586-5] [Reference Citation Analysis]
205 Pietropaolo G, Scarno G, Stabile H, Grimaldi A, Gismondi A, Santoni A, Sciumè G. NK cell and ILC heterogeneity in colorectal cancer. New perspectives from high dimensional data. Mol Aspects Med 2021;:100967. [PMID: 33941383 DOI: 10.1016/j.mam.2021.100967] [Reference Citation Analysis]
206 Ferreira MN, Choe JH. Guiding immunotherapy combinations: Who gets what? Adv Drug Deliv Rev 2021;178:113962. [PMID: 34481029 DOI: 10.1016/j.addr.2021.113962] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
207 Hegi-Johnson F, Rudd S, Hicks RJ, De Ruysscher D, Trapani JA, John T, Donnelly P, Blyth B, Hanna G, Everitt S, Roselt P, MacManus MP. Imaging immunity in patients with cancer using positron emission tomography. NPJ Precis Oncol 2022;6:24. [PMID: 35393508 DOI: 10.1038/s41698-022-00263-x] [Reference Citation Analysis]
208 Lin HM, Yeung N, Hastings JF, Croucher DR, Huynh K, Meikle TG, Mellett NA, Kwan EM, Davis ID, Tran B, Mahon KL, Zhang A, Stockler MR, Briscoe K, Marx G, Bastick P, Crumbaker ML, Joshua AM, Azad AA, Meikle PJ, Horvath LG. Relationship between Circulating Lipids and Cytokines in Metastatic Castration-Resistant Prostate Cancer. Cancers (Basel) 2021;13:4964. [PMID: 34638448 DOI: 10.3390/cancers13194964] [Reference Citation Analysis]
209 Debien V, Davidson G, Baltzinger P, Kurtz JE, Séverac F, Imperiale A, Pessaux P, Addeo P, Bachellier P, Su X, Davidson I, Chenard MP, Goichot B, Malouf GG. Involvement of Neutrophils in Metastatic Evolution of Pancreatic Neuroendocrine Tumors. Cancers (Basel) 2021;13:2771. [PMID: 34199561 DOI: 10.3390/cancers13112771] [Reference Citation Analysis]
210 Yang QF, Wu D, Wang J, Ba L, Tian C, Liu YT, Hu Y, Liu L. Development and validation of an individualized immune prognostic model in stage I-III lung squamous cell carcinoma. Sci Rep 2021;11:12727. [PMID: 34135424 DOI: 10.1038/s41598-021-92115-0] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
211 Yang L, Liu G, Li Y, Pan Y. The emergence of tumor-infiltrating lymphocytes in nasopharyngeal carcinoma: Predictive value and immunotherapy implications. Genes & Diseases 2021. [DOI: 10.1016/j.gendis.2021.07.002] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
212 Hou J, Karin M, Sun B. Targeting cancer-promoting inflammation - have anti-inflammatory therapies come of age? Nat Rev Clin Oncol 2021;18:261-79. [PMID: 33469195 DOI: 10.1038/s41571-020-00459-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
213 Almangush A, De Keukeleire S, Rottey S, Ferdinande L, Vermassen T, Leivo I, Mäkitie AA. Tumor-Infiltrating Lymphocytes in Head and Neck Cancer: Ready for Prime Time? Cancers 2022;14:1558. [DOI: 10.3390/cancers14061558] [Reference Citation Analysis]
214 You W, Cai Z, Sheng N, Yan L, Wan H, Wang Y, Ouyang J, Xie L, Wu X, Wang Z. Construction and Validation of Convenient Clinicopathologic Signatures for Predicting the Prognosis of Stage I-III Gastric Cancer. Front Oncol 2022;12:848783. [DOI: 10.3389/fonc.2022.848783] [Reference Citation Analysis]
215 Zhu T, Liu J, Beck S, Pan S, Capper D, Lechner M, Thirlwell C, Breeze CE, Teschendorff AE. A pan-tissue DNA methylation atlas enables in silico decomposition of human tissue methylomes at cell-type resolution. Nat Methods 2022;19:296-306. [DOI: 10.1038/s41592-022-01412-7] [Reference Citation Analysis]
216 Rigamonti A, Feuerhake F, Donadon M, Locati M, Marchesi F. Histopathological and Immune Prognostic Factors in Colo-Rectal Liver Metastases. Cancers (Basel) 2021;13:1075. [PMID: 33802446 DOI: 10.3390/cancers13051075] [Reference Citation Analysis]
217 Kondou R, Akiyama Y, Iizuka A, Miyata H, Maeda C, Kanematsu A, Watanabe K, Ashizawa T, Nagashima T, Urakami K, Shimoda Y, Ohshima K, Shiomi A, Ohde Y, Terashima M, Uesaka K, Onitsuka T, Nishimura S, Hirashima Y, Hayashi N, Kiyohara Y, Tsubosa Y, Katagiri H, Niwakawa M, Takahashi K, Kashiwagi H, Nakagawa M, Ishida Y, Sugino T, Notsu A, Mori K, Takahashi M, Kenmotsu H, Yamaguchi K. Identification of tumor microenvironment-associated immunological genes as potent prognostic markers in the cancer genome analysis project HOPE. Mol Clin Oncol 2021;15:232. [PMID: 34631056 DOI: 10.3892/mco.2021.2395] [Reference Citation Analysis]
218 De Keukeleire SJ, Vermassen T, Hilgert E, Creytens D, Ferdinande L, Rottey S. Immuno-Oncological Biomarkers for Squamous Cell Cancer of the Head and Neck: Current State of the Art and Future Perspectives. Cancers (Basel) 2021;13:1714. [PMID: 33916646 DOI: 10.3390/cancers13071714] [Reference Citation Analysis]
219 Li R, Lin Y, Wang Y, Wang S, Yang Y, Mu X, Chen Y, Gao Z. Characterization of the Tumor Immune Microenvironment in Lung Squamous Cell Carcinoma Using Imaging Mass Cytometry. Front Oncol 2021;11:620989. [PMID: 33869005 DOI: 10.3389/fonc.2021.620989] [Reference Citation Analysis]
220 Pan H, Pan J, Li P, Wu J. Immunologic Gene Sets Reveal Features of the Tumor Immune Microenvironment and Predict Prognosis and Immunotherapy Response: A Pan-Cancer Analysis. Front Immunol 2022;13:858246. [DOI: 10.3389/fimmu.2022.858246] [Reference Citation Analysis]
221 Li F, Li C, Cai X, Xie Z, Zhou L, Cheng B, Zhong R, Xiong S, Li J, Chen Z, Yu Z, He J, Liang W. The association between CD8+ tumor-infiltrating lymphocytes and the clinical outcome of cancer immunotherapy: A systematic review and meta-analysis. EClinicalMedicine 2021;41:101134. [PMID: 34585125 DOI: 10.1016/j.eclinm.2021.101134] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]